The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002311
- Lead Sponsor
- Mucos Pharma GmbH and Co
- Brief Summary
To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Saint Luke's - Roosevelt Hosp Ctr
🇺🇸New York, New York, United States
Saint Luke's - Roosevelt Hosp Ctr🇺🇸New York, New York, United States